冠心病合并心房颤动的抗栓治疗进展
李娜,杨新春
摘要(Abstract)：
<正>心房颤动(房颤)是临床上最常见的心律失常之一,其发病率随年龄增长而增加。全球房颤约为3350万例,预计2060年患病人数将再增加2倍~([1-2])。房颤和冠心病有诸多共同的危险因素,如年龄、高血压病、糖尿病等,临床实践中两种疾病常常易共存,约有1/3房颤患者合并冠心病~([3])。心房血栓和冠状动脉内血栓形成机制不同,两者抗栓治疗策略也不同。抗血小板药物治疗是冠心病二级预防的基础和关
关键词(KeyWords)： 冠心病;心房颤动;抗栓治疗
基金项目(Foundation): 国家自然科学基金(81500270)
作者(Author): 李娜,杨新春
参考文献(References)：
- [1]Chugh SS,Havmoeller R,Narayanan K,et al.Worldwide epidemiology of atrial fibrillation:a Global Burden of Disease2010 Study.Circulation,2014,129(8):837-847.
- [2]Krijthe BP,Kunst A,Benjamin EJ,et al.Projections on the number of individuals with atrial fibrillation in the European Union,from 2000 to 2060.Eur Heart J,2013,34(35):2746-2751.
- [3]Zoni-Berisso M,Lercari F,Carazza T,et al.Epidemiology of atrial fibrillation:European perspective.Clin Epidemiol,2014,6:213-220.
- [4]Camm AJ,Kirchhof P,Lip GY,et al.Guidelines for the management of atrial fibrillation:the task force for the management of atrial fibrillation of the European Society of Cardiology(ESC).Eur Heart J,2010,31(19):2369-2429.
- [5]Pisters R,Lane DA,Nieuwlaat R,et al.A novel user-friendly score(HAS-BLED)to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey.Chest,2010,138(5):1093-1100.
- [6]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society.Circulation,2014,130(23):e199-267.
- [7]Lamberts M,Gislason GH,Lip GY,et al.Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant:a nationwide cohort study.Circulation,2014,129(15):1577-1585.
- [8]中国老年学学会心脑血管病专业委员会.稳定性冠心病口服抗血小板药物治疗中国专家共识.中华心血管病杂志,2016,44(2):104-111.
- [9]Lip GY,Windecker S,Huber K,et al.Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions:a joint consensus document of the European Society of Cardiology Working Group on Thrombosis,European Heart Rhythm Association(EHRA),European Association of Percutaneous Cardiovascular Interventions(EAPCI)and European Association of Acute Cardiac Care(ACCA)endorsed by the Heart Rhythm Society(HRS)and Asia-Pacific Heart Rhythm Society(APHRS).Eur Heart J,2014,35(45):3155-3179.
- [10]Kirchhof P,Benussi S,Kotecha D,et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Eur Heart J,2016,37(38):2893-2962.
- [11]中华医学会心血管病学分会介入心脏病学组.中国经皮冠状动脉介入治疗指南(2016).中华心血管病杂志,2016,44(5):382-400.
- [12]Dewilde WJ,Oirbans T,Verheugt FW,et al.Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention:an open-label,randomised,controlled trial.Lancet,2013,381(9872):1107-1115.
- [13]Fiedler KA,Maeng M,Mehilli J,et al.Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DrugEluting Stent Implantation:The ISAR-TRIPLE Trial.J Am Coll Cardiol,2015,65(16):1619-1629.
- [14]Sarafoff N,Martischnig A,Wealer J,et al.Triple therapy with aspirin,prasugrel,and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.J Am Coll Cardiol.2013,61(20):2060-2066.
- [15]Gibson CM,Mehran R,Bode C,et al.Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.N Engl J Med,2016,375(25):2423-2434.